ATE548046T1 - Therapeutische verwendung von pulver von dunaliella - Google Patents

Therapeutische verwendung von pulver von dunaliella

Info

Publication number
ATE548046T1
ATE548046T1 AT04019206T AT04019206T ATE548046T1 AT E548046 T1 ATE548046 T1 AT E548046T1 AT 04019206 T AT04019206 T AT 04019206T AT 04019206 T AT04019206 T AT 04019206T AT E548046 T1 ATE548046 T1 AT E548046T1
Authority
AT
Austria
Prior art keywords
therapeutic use
dunaliella powder
subject
powder
dunaliella
Prior art date
Application number
AT04019206T
Other languages
German (de)
English (en)
Inventor
Aviv Shaish
Dror Harats
Original Assignee
Nikken Sohonsha Corp
Tel Hashomer Medical Res Infrastructure & Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikken Sohonsha Corp, Tel Hashomer Medical Res Infrastructure & Services Ltd filed Critical Nikken Sohonsha Corp
Application granted granted Critical
Publication of ATE548046T1 publication Critical patent/ATE548046T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04019206T 2003-09-24 2004-08-12 Therapeutische verwendung von pulver von dunaliella ATE548046T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/668,601 US7264813B2 (en) 2003-09-24 2003-09-24 Therapeutic uses of Dunaliella powder

Publications (1)

Publication Number Publication Date
ATE548046T1 true ATE548046T1 (de) 2012-03-15

Family

ID=34313520

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04019206T ATE548046T1 (de) 2003-09-24 2004-08-12 Therapeutische verwendung von pulver von dunaliella

Country Status (5)

Country Link
US (3) US7264813B2 (enExample)
EP (2) EP1522310B1 (enExample)
JP (5) JP5020463B2 (enExample)
AT (1) ATE548046T1 (enExample)
IL (1) IL162987A (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007210917A (ja) * 2006-02-08 2007-08-23 Kochi Univ 脂肪細胞縮小化剤、医薬品及び飲食品
WO2007109824A1 (en) * 2006-03-24 2007-10-04 Ian Simon Tracton Stable packaged dosage form and process therefor
JP2008222555A (ja) * 2007-03-08 2008-09-25 Nagasakiken Koritsu Daigaku Hojin アディポネクチン受容体発現増加剤
WO2009105048A2 (fr) * 2008-02-19 2009-08-27 Rached Smida Nouvelles applications du hdl reconstitué
EP2296682B8 (en) 2008-04-29 2018-07-04 Nikken Sohonsha Corporation Methods of treating ophthalmic disorders
US20100303989A1 (en) 2008-10-14 2010-12-02 Solazyme, Inc. Microalgal Flour
JP5733592B2 (ja) * 2008-10-20 2015-06-10 株式会社日健総本社 脂質異常治療薬の副作用防止物質
WO2010102056A1 (en) * 2009-03-03 2010-09-10 Solazyme, Inc. Methods of treating impaired glucose metabolism via administration of algal biomass
US9180152B2 (en) 2009-12-10 2015-11-10 Nikken Sohonsha Corporation Method for treating psoriasis
JP5736394B2 (ja) 2010-03-02 2015-06-17 ヴィシェイ−シリコニックス 半導体装置の構造及びその製造方法
US10098371B2 (en) 2013-01-28 2018-10-16 Solazyme Roquette Nutritionals, LLC Microalgal flour
FR3009619B1 (fr) 2013-08-07 2017-12-29 Roquette Freres Compositions de biomasse de microalgues riches en proteines de qualite sensorielle optimisee
GB201718822D0 (en) 2017-11-14 2017-12-27 Univ Greenwich Production of dunaliella
JP6947665B2 (ja) * 2018-03-13 2021-10-13 アイカ工業株式会社 光硬化性粘着樹脂組成物
US20220175860A1 (en) * 2019-04-01 2022-06-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Dunaliella alga preparation for prevention and/or treatment of a neurodegenerative disease, a disorder associated with protein misfolding and cognitive decline

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199895A (en) 1977-05-25 1980-04-29 Yeda Research And Development Co. Ltd. Production of glycerol, carotenes and algae meal
USPP4511P (en) 1978-06-26 1980-03-18 Yeda Research & Development Co. Ltd. Alga strain
DE3729209A1 (de) 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
IL87260A (en) * 1988-02-25 1991-12-15 Tanaka Yoshio Encapsulated food containing dunaliella algae and its production
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5219888A (en) 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
WO1993024454A1 (en) 1992-06-04 1993-12-09 Betatene Limited High cis beta-carotene composition
US6262109B1 (en) * 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
WO1997010819A1 (en) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists
EP0788353A1 (en) * 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Ppar gamma antagonists for treating obesity
IL119224A (en) 1996-09-09 2002-11-10 Hadasit Med Res Service Medicament for protection from effects of irradiation
JP3037628B2 (ja) * 1997-03-06 2000-04-24 マイクロアルジェコーポレーション株式会社 健康補助食品用軟カプセルの製法
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
EP1144997A3 (en) 1998-03-30 2002-08-28 The Regents of the University of California Methods and compounds for modulating nuclear receptor activity
DE69929996T2 (de) 1998-06-30 2006-11-16 Takeda Pharmaceutical Co. Ltd. Pharmazeutisches mittel zur behandlung von diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
AU776664B2 (en) 1998-12-23 2004-09-16 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
US6914073B2 (en) * 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US6593493B1 (en) 1999-09-14 2003-07-15 Ligand Pharmaceuticals, Inc. RXR modulators with improved pharmacologic profile
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
AU2002333655A1 (en) 2001-09-25 2003-04-07 Smithkline Beecham Corporation Bicyclic heterocycles as rxr ligands
IN189624B (enExample) * 2001-10-23 2003-03-29 Ajanta Pharma Ltd
JP3978582B2 (ja) * 2001-12-19 2007-09-19 株式会社日健総本社 カロチノイドの製造方法
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor

Also Published As

Publication number Publication date
EP1522310B1 (en) 2012-03-07
EP2269620A1 (en) 2011-01-05
US20080019997A1 (en) 2008-01-24
US7264813B2 (en) 2007-09-04
JP5020463B2 (ja) 2012-09-05
JP6490782B2 (ja) 2019-03-27
US20100221348A1 (en) 2010-09-02
JP2005097255A (ja) 2005-04-14
US7763255B2 (en) 2010-07-27
JP2016147916A (ja) 2016-08-18
JP5356946B2 (ja) 2013-12-04
US20050063991A1 (en) 2005-03-24
JP2018035200A (ja) 2018-03-08
JP2013177457A (ja) 2013-09-09
IL162987A (en) 2013-06-27
EP1522310A1 (en) 2005-04-13
JP6321074B2 (ja) 2018-05-09
HK1071845A1 (en) 2005-08-05
US8343549B2 (en) 2013-01-01
JP2009256392A (ja) 2009-11-05

Similar Documents

Publication Publication Date Title
ATE548046T1 (de) Therapeutische verwendung von pulver von dunaliella
IL184364A0 (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
WO2007124461A3 (en) Glp-1 compounds
WO2006083987A8 (en) Collaborative web page authoring
NO20065070L (no) Fremgangsmater for behandling av benkreftsmerte ved a administrere en nervevekstfaktorantagonist
EP1705634A4 (en) METHOD AND APPARATUS FOR COMPENSATING THE CHANGE OF A LIQUID CRYSTAL DISPLAY BY INTERVAL OF YEARS, COMPUTER PROGRAM, AND LIQUID CRYSTAL DISPLAY
WO2009062081A3 (en) Methods and compositions for antibody or vaccine therapy
WO2004101752A3 (en) Compounds for treatment of inflammation, diabetes and related disorders
AU2003251933A8 (en) Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
PL1781296T3 (pl) Pochodne chinazolinowe i ich zastosowanie w leczeniu nadpłytkowości
TW200741003A (en) Modulation of peroxisome proliferator-activated receptors
WO2006048877A3 (en) Treatment of b-cell malignancies with fgfr3 inhibitors
EP1757166A4 (en) DEVICE AND METHOD FOR COOKING GARLIC
WO2003044654A3 (en) Method for developing and managing large-scale web user interfaces
WO2006096740A3 (en) An apparatus and method for employing cloning for software development
Roane et al. Reduction of emergent dropping behavior during treatment of elopement
Pelizzo et al. Metabolic and Hormonal Changes in Pediatric Burn Patients: Mechanisms, Evidence, and Care Strategies
TW200607195A (en) Method of increasing surface work function of the ITO film by irradiation treatment of the excimer laser
Engelhaupt Do compact fluorescent bulbs reduce mercury pollution?
AU2002951338A0 (en) Method and computer program for the management of tabletop wargame campaigns
Cordes et al. P02-98 Monitoring of the metabolic syndrome in psychiatric inpatients
AU2003240254A1 (en) Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
Wright Interaction of the Plasma Melatonin Rhythm with other Hormone Rhythms During Development and on Various Light/Dark Cycles
Truyers et al. Intego in de praktijk (deel 2): Incidentie van waterpokken
Zheng et al. Geochemical Factors Affecting Release of U (VI) from Soils